Radically extended
healthspan for all
38+ million lives and counting
Healthspan is the period of life spent in good health, generally free from disease and disability.
Early stage healthtech venture capital fund investing in impactful health technology startups globally.
Our Mission
Healthtech investment is the key to extending healthspan for all.
Traditional healthcare is slow and ineffective. To radically extend healthspan for all, we believe healthcare needs to be exponentially more efficient and effective. Healthtech is leading this change.
Healthtech leverages technology to amplify the current health system. It connects and extends traditional health sectors with adjacent non-health sectors that easily reach billions.
Why Founders Choose Us
More Than Capital. A Partner.
We don't just write cheques. We provide the clinical, regulatory, and commercial expertise needed to navigate the complex healthcare landscape.
Specialists, Not Generalists
We are clinicians, scientists, and operators. We understand the science, the regulatory pathways (FDA/CE), and the clinical workflows required for adoption.
Global Commercialisation
Healthcare is local, but innovation is global. We bridge Asian, European, and US markets, helping portfolio companies expand internationally from day one.
Hands-On Validation
We help structure clinical trials and pilot programs through our network of hospital partners. We de-risk the path from bench to bedside.
Our partners have led digital transformations at top-tier firms and founded successful healthtech startups. We've sat in your seat.
Changemakers. Not just investors.
We seek and support visionary, passionate, and persistent founders who are creating transformative healthtech companies today that shape our vision of tomorrow.
Active Expertise
Experienced healthtech operators that actively partner with founders crossing the chasm from early to growth stage.
Global Ecosystem
Access to Verge's global network of leading companies, investors, and institutions to help your company scale.
Portfolio Synergies
Collaboration with our extended portfolio on R&D, commercial distribution, and clinical trials.
Investment Scope
Where we invest in global healthtech.
We invest in & help scale:
Technologies that solve large unmet needs in health and platforms that can reach millions.
AI and Data Analytics
Solutions that use artificial intelligence and/or data analysis techniques to extract actionable and valuable insights and patterns within healthcare data.
Next Gen Diagnostics
Advanced diagnostic tools incorporating cutting-edge detection technologies, algorithms and/or novel biomarkers, to diagnose and/or monitor diseases earlier.
Breakthrough Smart Devices
Highly innovative wearable or portable devices that incorporate smart technologies to monitor, diagnose, or treat health conditions.
Digital Health Platforms
Online platforms that facilitate various health services such as telemedicine, remote patient monitoring, chronic disease management, and patient engagement.
Digital Therapeutics
Digital systems or software used as therapeutic interventions for treating, managing, or preventing a specific health condition.
Healthcare SaaS
Software-as-a-Service platforms specifically designed for healthcare that do not directly face patients, such as EHR, billing, and inventory management.
Global Footprint
Global healthtech investment has no borders.
38,340,535 lives impacted across our global portfolio.
36
Companies
50
Countries
22
LMIC Markets
Portfolio
Healthtech startups backed by Verge.

Arogga
Vertically integrated digital pharmacy in Bangladesh with proprietary fulfilment infrastructure delivering authentic medications

Bot MD
Chat-first automation platform that embeds AI agents into messaging apps to digitise patient engagement workflows

BrainCapture
Low-cost, high quality, smartphone pairable EEG amplifier with a novel cap that allows for remote neurology diagnostics

CareLoop Health
Predictive digital therapeutics for people living with serious mental illness, starting with psychosis
ChestPal
The world’s most affordable and intelligent digital stethoscope for lung sounds (and soon heart)

CuboAi
Proactive AI for your baby's sleep, safety, health, and memories
Insights
Latest news & updates
Citrini on X: 'Would you swallow this robot?'
An analyst from Citrini, a research firm, is visiting various robotics companies. During these site visits, the analyst shared a photograph of a swallowable robotic device with the caption: 'Would you swallow this robot?'. The post, which can be viewed at https://x.com/citrini/status/2089744013976826195, sparked engagement from other users, including Andrew Kang, who commented that investigating such devices constitutes 'mandatory due dilligence for analysts' (https://x.com/Rewkang/status/2089787980185563238).
PillBot — Autonomous Capsule Endoscopy Platform
California startup Endiatx has developed PillBot, a swallowable capsule equipped with a camera, lights, and micro-propellers that actively "swims" inside the stomach to stream real-time video directly to a doctor's tablet—offering a non-invasive, sedation-free alternative to traditional gastroscopies. Tested by Adam Savage, the procedure takes just 10 minutes after drinking water and naturally passes through the digestive system once the battery expires. The company's lineup includes PillVue (real-time imaging), PillBot (autonomous mobility), and Cortex (workstation), with Endiatx targeting FDA 510(k) submission and a commercial launch.
98% of Cancer Patients Outside the US Miss Genomic Testing. Can AI Change That?
In an episode of the 'Diagnosing Dx' podcast, host David Filby interviews Travis Wold, CEO of Imagenomix Corp. The discussion highlights a critical disparity in oncology care: approximately 98% of cancer patients outside the United States do not receive Next-Generation Sequencing (NGS) genomic testing. Imagenomix is leveraging artificial intelligence to address this gap by analyzing standard H&E pathology images to identify mutation signals, potentially helping to screen patients who would benefit most from confirmatory genomic testing. Key topics include the limitations of current genomic testing access globally, the use of AI to reduce the cost and volume of unnecessary NGS testing, commercial strategies for digital pathology partnerships, and the future potential for AI to support precise oncology treatment decisions.
Our Team
Seasoned investors.
Former operators.
Ready to build
the future?
We are looking for visionary founders solving the hardest problems in healthcare. If that's you, we want to hear from you.